GST2 as A Potential Drug Target and Biomarker (G2953)

Target Name: GSTT2

NCBI ID: G2953

GSTT2

GST2 as A Potential Drug Target and Biomarker

GSTT2 (GST2-HUMAN) is a gene that encodes a protein known as GST2. GST2 is a member of the GST family of transmembrane proteins, which are involved in the detoxification of xenobiotics and other harmful substances. GST2 is primarily expressed in the liver and other tissues, and it is involved in the detoxification of a wide variety of compounds, including drugs and other toxins.

GST2 has been identified as a potential drug target due to its involvement in drug metabolism and its expression in the liver, which is a key organ for drug elimination. Many drugs are metabolized by the liver and other tissues, and GST2 is involved in the detoxification and elimination of these drugs. This makes GST2 a potentially interesting target for drug developers because drugs that are able to inhibit the activity of GST2 could potentially be administered to treat a wide range of diseases and disorders.

In addition to its potential as a drug target, GST2 has also been identified as a potential biomarker for a variety of diseases. For example, GST2 has been shown to be expressed in the liver tissues of individuals with nonalcoholic steatohepatitis (NASH), a common type of liver disease that is characterized by the buildup of fat in the liver. Additionally, GST2 has been shown to be involved in the development and progression of certain types of cancer, which makes it a potentially interesting biomarker for cancer.

GST2 is also considered as a potential therapeutic target for treating certain neurological disorders. The GST2 gene has been shown to be involved in the development and progression of certain neurological disorders, such as Alzheimer's disease and Parkinson's disease. This suggests that GST2 may be a potential therapeutic target for these disorders.

Another potential application of GST2 as a drug target is its involvement in the regulation of the immune system. GST2 has been shown to be involved in the regulation of the immune response, which suggests that it may play a role in the development of certain autoimmune diseases. This makes GST2 a potentially interesting target for the development of new treatments for autoimmune diseases.

In conclusion, GSTT2 (GST2-HUMAN) is a gene that encodes a protein involved in the detoxification of xenobiotics and other harmful substances. Its potential as a drug target and biomarker make it an interesting target for drug developers and researchers. Further studies are needed to fully understand the role of GST2 in disease and to develop new treatments based on its potential as a drug target.

Protein Name: Glutathione S-transferase Theta 2 (gene/pseudogene)

Functions: Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles (PubMed:1417752). Has a sulfatase activity (PubMed:1417752)

The "GSTT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSTT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets